Navigation Links
Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
Date:12/2/2008

SOUTH SAN FRANCISCO, Calif., Dec. 2 /PRNewswire/ --Cerimon Pharmaceuticals, Inc. announced today that James S. Shannon, M.D., has been appointed to the Company's Board of Directors. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior development positions, most recently serving as Head of Global Development at Novartis Pharma AG in Basel, Switzerland.

"We are thrilled to welcome Dr. Shannon to our Board of Directors," stated Paul J. Sekhri, Chief Executive Officer of Cerimon Pharmaceuticals. "Dr. Shannon's expertise in identifying and advancing drug development candidates will be of great value as we seek to expand and deepen Cerimon's clinical-stage pipeline."

Dr. Shannon began his career in the pharmaceutical industry at Sterling Winthrop, where he attained the position of Senior Vice President, Clinical Development. Dr. Shannon headed Global Clinical Development during Sterling's alliance with Sanofi to develop Clopidogrel (Plavix(R)). Following this, Dr. Shannon joined Sandoz in Switzerland as Head of Drug Registration and Regulatory Affairs. He spearheaded the integration of R&D programs during Sandoz' merger with Ciba-Geigy, creating the renowned Novartis pipeline. Subsequently, Dr. Shannon held senior development positions at Novartis, ultimately being named Head of Global Development. Under Dr. Shannon's leadership, numerous drugs were developed and approved, including Diovan(R), Tekturna(R), Gleevec(R), Femara(R), Zometa(R), Reclast(R), Lucentis(R) (ex-US), Starlix(R), Visudyne(R) and Xolair(R).

Dr. Shannon received his undergraduate and postgraduate degrees from Queen's University of Belfast, where he was trained in medicine and cardiology. He also became a Member of the Royal College of Physicians (UK).

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for pain and inflammation. The Company's lead product, its topical diclofenac patch, recently reported positive Phase II results and plans to initiate the patch Phase III development program in 1Q 2009. Cerimon is financed by the premier investors, MPM, Normura Phase4 and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
2. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
5. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
6. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
11. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... ... North Carolina, and engages Timothy Reinhardt to manage the new site. , Tim ... Pfizer Inc, with his most recent role as the Director of Manufacturing and ...
(Date:6/22/2017)... Wendelsheim, Germany (PRWEB) , ... June 22, 2017 ... ... , is taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, ... We all know someone who suffers from hay fever, urticaria, asthma, atopic eczema ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... media network RegMedNet has produced a Spotlight series on ... scholarly reviews and perspectives by leading experts on the unique regulatory challenges of ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell ... years until the first data on cross-contamination of human cell lines with HeLa cells ... increasing issue in cell culture labs and is associated with dramatic consequences for research. ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):